Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy

#3626

Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Aim(s): To update our results from our publication in Cancer (DOI: 10.1002/cncr.34191r) as we now have an additional 33 months of follow up.

Materials and methods: The updated analysis of our retrospective review of the long-term toxicity and survival outcomes of 104 patients with advanced NETs treated on four phase II clinical trials with 177Lu-Octreotate PRRT plus concurrent chemotherapy (mostly capecitabine or capecitabine/temozolomide). Median follow-up of the 25% of patients who are still alive is 11 years (range 8 - 17 years), which represents the longest follow-up study of 177Lu-Octreotate PRRT for NETs to date.

Conference:

Presenting Author: Ransom D

Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,

Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,